1Xian H, Song Y, Li Y, et al. Qiliqiangxin regulates the balance between tumor necrosis factor - alpha and interleukin - 10 and improves cardiac function in rats with myocardial infarction [ J ]. Cell Immuno1,2009,260 ( 1 ) :51 - 55.
2Zou Y, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice[ J ]. J Cardiovasc Pharma- col,2012,59 (3) :268 - 280.
3Liu W, Chen J, Xu T, et al. Qiliqiangxin improves cardiac func- tion in spontaneously hypertensive rats through the inhibition of cardiac ehymase [ J ]. Am J Hypertens, 2012,25 ( 2 ) : 250 - 260.
4Wei Y ,Liu X ,Hou L,et al. Qiliqiangxin affects L type ca(2 + ) current in the normal and hypertrophied rat heart [ J ]. Evid Based Complement Alternat Med,2012 : 131830.
5Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese tuedieinal formula Reaigar - Indigo naturalis as an ef- fective treatment tbr promyeloeytic leukemia [ J ]. Proc Natl Acad Sci U S A,2008,105 ( 12 ) :4826 - 4831.
6Zhang L, Liu Y, Lu XT, et al. Traditional Chinese medication Tongxinluo,dose - dependently enhances stability of vulnerable plaques:a comparison with a high -dose simvastatin therapy [ J]. Am J Physiol Heart Cite Physiol,2009,297 (6) : H2004 - H2014.
7Li XD, Y ang Y.I, Geng YJ,et al. Tongxinluo reduces myocardi- al no - reflow and ischemia - reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway[ J]. Am J Physiol Heart Circ Physiol,2010,299(4) :H1255 -H126l.
8Hu J,Liu YF,Wu CF,et al. Long- term efficacy and safety of all - trans retinoic acid/arsenic trioxide - based therapy in newly diagnosed acute promyelocytic leukemia [ J ]. Proc Natl Acad Sci U S A,2009,106(9) :3342 -3347.
9Zhuo Q, Yang X, Wu T, et al. Tongxinluo capsule for acute stroke [ J ]. Coehrane Database Syst Rev, 2008, ( 4 ) : CD004584.
10Janicki JS, Levick SP. The convergence of ancient chinese medicine with modern therapeutics to prevent cardiac fibrosis [J]. Am J Hypertens,2012,25(2) :139.
